| Line 392: | Line 392: | ||
*Citation: Gravely, S., Thrasher, J. F., Cummings, K. M., Ouimet, J., McNeill, A., Meng, G., Lindblom, E. N., Loewen, R., O’Connor, R. J., Thompson, M. E., Hitchman, S. C., Hammond, D., Heckman, B. W., Borland, R., Yong, H.-H., Elton-Marshall, T., Bansal-Travers, M., Gartner, C., and Fong, G. T. (2019) Discussions between health professionals and smokers about nicotine vaping products: results from the 2016 ITC Four Country Smoking and Vaping Survey. Addiction, 114( S1): 71– 85. https://doi.org/10.1111/add.14527. | *Citation: Gravely, S., Thrasher, J. F., Cummings, K. M., Ouimet, J., McNeill, A., Meng, G., Lindblom, E. N., Loewen, R., O’Connor, R. J., Thompson, M. E., Hitchman, S. C., Hammond, D., Heckman, B. W., Borland, R., Yong, H.-H., Elton-Marshall, T., Bansal-Travers, M., Gartner, C., and Fong, G. T. (2019) Discussions between health professionals and smokers about nicotine vaping products: results from the 2016 ITC Four Country Smoking and Vaping Survey. Addiction, 114( S1): 71– 85. https://doi.org/10.1111/add.14527. | ||
*Acknowledgement: This study was supported by grants from the US National Cancer Institute (P01 CA200512), the Canadian Institutes of Health Research (FDN-148477) and by the National Health and Medical Research Council of Australia (APP 1106451). S.G. was funded by a 3-year Canadian Cancer Society (CCS) Career Development Award in Cancer Prevention (703858). G.T.F. was supported by a Senior Investigator Award from the Ontario Institute for Cancer Research. B.W.H. was supported by NIDA (K23 DA041616). | *Acknowledgement: This study was supported by grants from the US National Cancer Institute (P01 CA200512), the Canadian Institutes of Health Research (FDN-148477) and by the National Health and Medical Research Council of Australia (APP 1106451). S.G. was funded by a 3-year Canadian Cancer Society (CCS) Career Development Award in Cancer Prevention (703858). G.T.F. was supported by a Senior Investigator Award from the Ontario Institute for Cancer Research. B.W.H. was supported by NIDA (K23 DA041616). | ||
===2017: [https://www.bmj.com/content/358/bmj.j3262 E-cigarette use and associated changes in population smoking cessation: evidence from US current population surveys]=== | |||
*This study, based on the largest representative sample of e-cigarette users to date, provides a strong case that e-cigarette use was associated with an increase in smoking cessation at the population level. We found that e-cigarette use was associated with an increased smoking cessation rate at the level of subgroup analysis and at the overall population level. It is remarkable, considering that this is the kind of data pattern that has been predicted but not observed at the population level for cessation medication, such as nicotine replacement therapy and varenicline. This is the first statistically significant increase observed in population smoking cessation among US adults in nearly a quarter of a century. These findings need to be weighed carefully in regulatory policy making and in the planning of tobacco control interventions. | |||
*[https://www.bmj.com/content/bmj/358/bmj.j3262.full.pdf PDF Version] | |||
*Citation: Zhu S, Zhuang Y, Wong S, Cummins S E, Tedeschi G J. E-cigarette use and associated changes in population smoking cessation: evidence from US current population surveys BMJ 2017; 358 :j3262 doi:10.1136/bmj.j3262 | |||
*Acknowledgement: This study was supported by the National Cancer Institute of the National Institutes of Health under the State and Community Tobacco Control (SCTC) Initiative (award No U01CA154280). | |||
edits